Skip to main content
Premium Trial:

Request an Annual Quote

Delve Bio: Jim Stuart, Jay Wohlgemuth

Delve Bio, an infectious disease diagnostics firm that uses metagenomic sequencing, has appointed Jim Stuart as chief commercial officer and Jay Wohlgemuth as a company director.

Stuart joins the company from Invitae, where he was senior VP of commercial. Prior to that, he was sales director at Caris Life Science and director of diagnostic sales at Ambry Genetics. Wohlgemuth is managing partner at Trusted Health Advisors. Before that, he was chief medical officer and senior VP of research and development for medical and population health at Quest Diagnostics. Prior to that, he was director of clinical diagnostics, immunology, and tissue growth and repair at Genentech.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.